BCRX - BioCryst Pharmaceuticals, Inc.
| Previous Close | 7.31 |
| Open | 7.31 |
| Bid | 7.86 x 800 |
| Ask | 8.00 x 2900 |
| Day's Range | 7.22 - 7.90 |
| 52 Week Range | 4.25 - 8.31 |
| Volume | 1,067,799 |
| Avg. Volume | 525,934 |
| Market Cap | 862.875M |
| Beta (3Y Monthly) | 2.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.50 |
- Thomson Reuters StreetEvents•yesterday
Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT
Q3 2018 BioCryst Pharmaceuticals Inc Earnings Call
- GlobeNewswire•2 days ago
BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly.
- GlobeNewswire•10 days ago
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 08, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies London Healthcare.
- Zacks•12 days ago
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -12.00% and -42.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•12 days ago
BioCryst: 3Q Earnings Snapshot
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- GlobeNewswire•12 days ago
BioCryst Reports Third Quarter 2018 Financial Results
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced.
- GlobeNewswire•13 days ago
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual.
- Zacks•19 days ago
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•25 days ago
BioCryst to Report Third Quarter 2018 Financial Results on November 6
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial.
- GlobeNewswire•last month
Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•last month
Grifols (GRFS) Surges: Stock Moves 5.4% Higher
Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- GlobeNewswire•2 months ago
BioCryst Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will present at the Cantor Fitzgerald Global.
- GlobeNewswire•2 months ago
BioCryst Receives Additional $3.5 Million to Fund Clinical Trials of Galidesivir in Yellow Fever
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst an additional $3.5 million to support clinical trials of galidesivir in patients with yellow fever. Yellow fever represents a significant unmet medical need and a new potential use of galidesivir. With this additional $3.5 million contract amendment, the NIAID development contract for galidesivir now totals $43.0 million.
Market Realist•2 months agoWhat Sarepta Therapeutics’ Valuation Trend Indicates
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
- Motley Fool•2 months ago
Here's Why BioCryst Pharmaceuticals Rose 21.3% in August
Believe it or not, share prices rose after the company announced a share offering.
- MarketWatch•2 months ago
BioCryst stock surges 6% premarket after winning $35 million CDC contract for flu therapy
BioCryst Pharmaceuticals Inc. shares (bcrx) surged more than 6% premarket on the news that it has won a $35 million, five-year contract from the Centers for Disease Control and Prevention for up to 50,000 doses of its antiviral flu therapy Rapivab. The CDC will place the medication in the Strategic National Stockpile, a supply of potentially life-saving medicines for use in a public-health emergency. Rapivab is used to treat acute flu in patients two years and older who have shown symptoms for more than two days.
- GlobeNewswire•2 months ago
CDC Awards BioCryst $35 Million RAPIVAB® Contract for Strategic National Stockpile
BioCryst Pharmaceuticals, Inc. (BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period. The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency. “We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security,” said Jon Stonehouse, chief executive officer of BioCryst.
- Benzinga•2 months ago
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...
- GlobeNewswire•2 months ago
CORRECTION -- BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
In a release issued under the same headline earlier today by BioCryst Pharmaceuticals, Inc. (BCRX), please note that in the first line of the table, the values for the change from baseline in VAS score through 4 hours under BCX7353 Treated Attacks and Placebo Treated Attacks are numbers, not percentages as previously published. Please also note a footnote has been added to the end of the table within the release, which notes baseline composite VAS scores for both BCX7353 treated attacks and placebo treated attacks. RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p
- GlobeNewswire•2 months ago
BioCryst Reports Positive Results Across Multiple Endpoints in ZENITH-1 Trial of Oral BCX7353 as Acute Therapy for Hereditary Angioedema (HAE) Attacks
BioCryst Pharmaceuticals, Inc. (BCRX) today announced initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p
- GlobeNewswire•3 months ago
BioCryst Pharmaceuticals to Present at the Baird Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 29, 2018-- BioCryst Pharmaceuticals, Inc. today announced that the company will present at the Baird Global Healthcare Conference in New York on Thursday, September 6, ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BCRX earnings conference call or presentation 7-Aug-18 3:00pm GMT
Q2 2018 BioCryst Pharmaceuticals Inc Earnings Call
